The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. That, and how the agency precisely will oversee UK device regulation in the future, are front of mind for industry.

The UK’s new medical device registration system, one element of the post-Brexit transition being overseen by the MHRA, is going more or less to plan in the early stages of the standstill period.

Manufacturing and supply chain resilience ensured that BTG Specialty Pharma met its sales target in the COVID-affected 2020. Its president, Anthony Higham, explained how this was possible while the company busily  ̶  and quietly – sought new ownership, and all under the shadow of Brexit.

A TOPRA webinar gave UK-based pharma firms an idea of the complexities and uncertainties they will need to deal with when placing medicines on the market in different parts of the UK.

Recognition of EU/EEA batch testing of imported medicines by UK will not be ending on 1 January 2023, and companies will be given two years notice if anything changes, says MHRA.

Having to set up duplicate testing facilities in the EU and the UK is an expensive business, so pharmaceutical companies are relieved that the UK is giving them some extra breathing space.

A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.

Waiting until the grace period expires before making a product application under the EU MDR or IVDR is a gambit that could easily misfire, TEAM-NB warns.

PAGB CEO Michelle Riddalls tells HBW Insight what it was like to lead the UK consumer health industry during 2020 in the middle of Brexit and COVID-19.